DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prakash, C.
Right arrow Articles by Howard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prakash, C.
Right arrow Articles by Howard, H.

0090-9556/97/2502-0206-0218$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 2

Metabolism and Excretion of the Novel Antipsychotic Drug Ziprasidone in Rats after Oral Administration of a Mixture of 14C- and 3H-Labeled Ziprasidone

Chandra Prakash, Amin Kamel, Wayne Anderson, and Harry Howard

Departments of Drug Metabolism (C.P., A.K., W.A.) and Medicinal Chemistry (H.H.), Central Research Division, Pfizer Inc.

The metabolism and excretion of ziprasidone (5-[2-{4-(1,2-benzisothiazol-3-yl)piperazin-1-yl}ethyl]-6-chloroindolin-2-one hydrochloride hydrate) were studied in Long Evans rats after oral administration of a single dose of a mixture of 14C- and 3H-labeled ziprasidone. The radioactive dose was quantitatively recovered over 7 days in both male and female rats. The percentage of the dose excreted in urine, bile, and feces of rats was 21.6, 19.2, and 55.6%, respectively. The total excretion in urine and bile suggested that at least 41% of the drug was absorbed. Absorption of ziprasidone was rapid, and the mean plasma concentrations of the unchanged drug and metabolites were slightly higher in the female rats than in the males. The maximal plasma concentrations for ziprasidone and metabolites were reached at 1 hr in both male and female rats. Based on AUC (0-12 hr) values, approximately 59 and 52% of the circulating radioactivity (average of 14C and 3H) was attributable to metabolites in male and female rats, respectively. Ziprasidone was extensively metabolized in rats, and only a small amount of ziprasidone was excreted as unchanged drug. Twelve metabolites were identified by ion spray LC/MS, using a combination of parent ion and product ion scanning techniques. The structures of eight metabolites were unambiguously confirmed by coelution on HPLC with synthetic standards, and four additional metabolites were partially identified. There was a gender-related difference in the excretion of urinary metabolites in Long Evans rats. The major route of metabolism in male rats involved N-dealkylation. In female rats the major metabolites were due to oxidation at the benzisothiazole ring. Based on the structures of these metabolites, four major and two minor routes of metabolism of ziprasidone were identified. The major routes included 1) N-dealkylation of the ethyl side chain attached to the piperazinyl nitrogen, 2) oxidation at the sulfur, resulting in the formation of sulfoxide and sulfone, 3) oxidation on the benzisothiazole moiety (other than sulfur), and 4) hydration of the Cdouble bond N bond and subsequent oxidation at the sulfur of the benzisothiazole moiety. The minor routes involved N-oxidation on the piperazine ring and hydrolysis of the oxindole moiety.


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Z. Miao, A. Kamel, and C. Prakash
CHARACTERIZATION OF A NOVEL METABOLITE INTERMEDIATE OF ZIPRASIDONE IN HEPATIC CYTOSOLIC FRACTIONS OF RAT, DOG, AND HUMAN BY ESI-MS/MS, HYDROGEN/DEUTERIUM EXCHANGE, AND CHEMICAL DERIVATIZATION
Drug Metab. Dispos., July 1, 2005; 33(7): 879 - 883.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. A. Tschirret-Guth and H. B. Wood
SUBSTITUENT EFFECT ON THE REDUCTIVE N-DEARYLATION OF 3-(INDOL-1-YL)-1,2-BENZISOXAZOLES BY RAT LIVER MICROSOMES
Drug Metab. Dispos., August 1, 2003; 31(8): 999 - 1004.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. Prakash and V. Soliman
Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats. Differentiation of regioisomeric glucuronides by LC/MS/MS
Drug Metab. Dispos., November 1, 1997; 25(11): 1288 - 1297.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
C. Prakash, A. Kamel, J. Gummerus, and K. Wilner
Metabolism and Excretion of a New Antipsychotic Drug, Ziprasidone, in Humans
Drug Metab. Dispos., July 1, 1997; 25(7): 863 - 0.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
C. Prakash, A. Kamel, and D. Cui
Characterization of the Novel Benzisothiazole Ring-Cleaved Products of the Antipsychotic Drug Ziprasidone
Drug Metab. Dispos., July 1, 1997; 25(7): 897 - 901.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.